Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia

International Journal of Impotence Research

Volumn 19, Issue 5, 2007, Pages 480-485

  Rosen, R ^a   Seftel, A ^a   Roehrborn, C G ^a  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

Author keywords

Alfuzosin; Benign prostatic hyperplasia; Ejaculatory dysfunction; Erectile dysfunction; Lower urinary tract symptoms; Sexual function

Indexed keywords

ALFUZOSIN; PLACEBO;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOUBLE-BLIND METHOD; EJACULATION; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PENILE ERECTION; PROSTATIC HYPERPLASIA; QUINAZOLINES;

EID: 34548380066     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901554     Document Type: Article

References (23)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
2. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-311.
3. Leliefeld HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int 2002; 89: 208-213.
4. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-649.
5. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824-837.
6. van Moorselaar RJ, Hartung R, Emberton M, Harving N, Matzkin H, Elhilali M et al. Alfuzosin 10mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95: 603-608.
7. Mottet N, Bressolle F, Delmas V, Robert M, Costa P. Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol 2003; 44: 101-105.
8. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10mg once daily versus alfuzosin 2.5mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 2000; 37: 306-313.
9. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 953-959.
10. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005; 95: 1006-1012.
11. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257-261.
12. Marks LS, Roehrborn CG, Gittelman M, Kim D, Forrest J, Jacobs S. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. Urology 2003; 62: 888-893.
13. Ahtoy P, Chretien P, Dupain T, Rauch C, Rouchouse A, Delfolie A. Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. Int J Clin Pharmacol Ther 2002; 40: 289-294.
14. Resnick MI, Roehrborn CG. Rapid onset of action with alfuzosin 10mg once daily in men with benign prostatic hyperplasia: a randomized placebo-controlled trial. Prostate Cancer Prostatic Dis 2007; 10: 155-159.
15. Schou J, Holm NR, Meyhoff HH. Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1996; 179: 119-122.
16. Hansen BJ, Flyger H, Brasso K, Schou J, Nordling J, Thorup Andersen J et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 1995; 76: 451-458.
17. FLOMAX (tamsulosin hydrochloride) [prescribing information]. Boehringer Ingelheim Pharmaceuticals Inc.: Ridgefield, CT, 2005.
18. Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD. Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: 777-782.
19. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002; 324: 1059-1061.
20. Panser LA, Rhodes T, Girman CJ, Guess HA, Chute CG, Oesterling JE et al. Sexual function of men ages 40 to 79 years: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. J Am Geriatr Soc 1995; 43: 1107-1111.
21. Vallancien G, Emberton M, Harving N, van Moorselaar RJ. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257-2261.
22. Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I. The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. Br J Urol 1998; 82: 842-846.
23. Tubaro A, Polito M, Giambroni L, Famulari C, Gange E, Ostardo E. Sexual function in patients with LUTS suggestive of BPH. Eur Urol 2001; 40(Suppl 1): 19-22.